Cytosorbents (NASDAQ:CTSO) Receives "Sell (E+)" Rating from Weiss Ratings

Key Points

• Cytosorbents (NASDAQ:CTSO) has received a "Sell (E+)" rating from Weiss Ratings, which may impact investor sentiment regarding the stock.
• Contrastingly, D. Boral Capital has given the stock a "buy" rating with a price target of $10.00, amidst a consensus average rating of "Hold" and a price target of $5.50.
• The company's stock is currently trading at $0.93, with a market capitalization of $58.05 million and a negative net margin of 25.58%.

Cytosorbents (NASDAQ:CTSO - Get Free Report)'s stock had its "sell (e+)" rating restated by Weiss Ratings in a note issued to investors on Tuesday,Weiss Ratings reports.

Separately, D. Boral Capital reissued a "buy" rating and issued a $10.00 price target on shares of Cytosorbents in a report on Tuesday, September 16th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $5.50.

Cytosorbents Stock Performance

Shares of CTSO stock traded down $0.01 on Tuesday, reaching $0.93. The stock had a trading volume of 15,708 shares, compared to its average volume of 171,350. The company has a quick ratio of 1.96, a current ratio of 2.34 and a debt-to-equity ratio of 1.24. The firm's 50-day moving average is $0.96 and its two-hundred day moving average is $0.99. The firm has a market capitalization of $58.05 million, a price-to-earnings ratio of -5.44 and a beta of 1.28. Cytosorbents has a 12 month low of $0.71 and a 12 month high of $1.61.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last issued its earnings results on Friday, January 3rd. The medical research company reported ($0.08) earnings per share (EPS) for the quarter. The firm had revenue of $8.61 million during the quarter. Cytosorbents had a negative net margin of 25.58% and a negative return on equity of 111.97%. On average, research analysts expect that Cytosorbents will post -0.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Goldman Sachs Group Inc. increased its holdings in shares of Cytosorbents by 149.2% during the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company's stock worth $63,000 after purchasing an additional 37,519 shares during the period. CM Management LLC boosted its position in shares of Cytosorbents by 36.3% during the 1st quarter. CM Management LLC now owns 954,076 shares of the medical research company's stock worth $954,000 after acquiring an additional 254,076 shares in the last quarter. Skylands Capital LLC boosted its position in shares of Cytosorbents by 7.9% during the 1st quarter. Skylands Capital LLC now owns 3,002,702 shares of the medical research company's stock worth $3,003,000 after acquiring an additional 221,080 shares in the last quarter. Finally, Avenir Corp boosted its position in shares of Cytosorbents by 63.1% during the 1st quarter. Avenir Corp now owns 5,044,918 shares of the medical research company's stock worth $5,045,000 after acquiring an additional 1,950,972 shares in the last quarter. 32.87% of the stock is owned by institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.